Following safety concerns at a planned review, Genmab’s collaboration partner ‘Janssen’ has decided to terminate the phase Ib/II study of Darzalex in combination with Roche’s PD-L1 antibody (Tecentriq) for previously treated non-small cell lung cancer. The findings of the study prompted Janssen to discontinue the phase I study of Darzalex along with Janssen’s PD-1 blocker for multiple myeloma as well.
07 Jun 2018
Two solid tumour studies discontinued
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Two solid tumour studies discontinued
Genmab A/S (GMAB:WBO) | 0 0 1.3% | Mkt Cap: 66,508m
- Published:
07 Jun 2018 -
Author:
Sumit Sayal -
Pages:
2
Following safety concerns at a planned review, Genmab’s collaboration partner ‘Janssen’ has decided to terminate the phase Ib/II study of Darzalex in combination with Roche’s PD-L1 antibody (Tecentriq) for previously treated non-small cell lung cancer. The findings of the study prompted Janssen to discontinue the phase I study of Darzalex along with Janssen’s PD-1 blocker for multiple myeloma as well.